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Abstract
Patients with cardiogenic shock are not all the same. They present with a variety of hemodynamic profiles and other
features that may allow us to create specific phenotypes. It is possible that phenotyping these patients at presentation may then
help us to identify the optimal and earliest therapies that will improve outcomes and, at the same time, help us to overcome
some of the heterogeneity currently undermining clinical trials.
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Background
The guidelines for and definitions of cardiogenic shock
are slowly evolving. Put simply, cardiogenic shock is a low
cardiac output state that leads to end-organ hypoperfusion,
tissue hypoxemia, and its sequelae. Ten years ago, a specific
phenotype for hemodynamic shock was investigated, and
separate phenotypes for cardiogenic hypovolemic shock were
presented. However, we know now that not all cardiogenic
shock is created equal. Patients in the cardiac intensive care
unit with cardiogenic shock may have very different baseline
characteristics, illness severity, shock presentations, and
hemodynamic profiles.

Cardiogenic Shock Phenotypes
In 2017, the American Heart Association published a
scientific statement that emphasized and reintroduced the
concepts involved in understanding and managing cardiogenic
shock.1 There are multiple phenotypic and hemodynamic
presentations for cardiogenic shock that include combinations
of wet and dry volume status with warm and cold peripheral
circulation. The classifications presented were extrapolated
largely from the acute heart failure literature, but they were
limited by the lack of research available at the time. Indeed,
patients can present with classic cardiogenic shock in which

their cardiac filling pressures and systemic vascular resistance
are elevated; this presentation is the classic cold and wet
phenomenon. Other patients may present in vasodilatory
cardiogenic shock and are relatively euvolemic with normal
cardiac filling pressures. In fact, the seminal SHOCK Trial
and Registry found that a quarter of patients presented with
cardiogenic shock and a low systemic vascular resistance—an
allusion to a sepsis-like phenotype for patients who are
actually in cardiogenic shock.2
Thus, without question, cardiogenic shock has multiple
phenotypes. The term phenotype means a set of observable
characteristics of an individual brought about by the genotype
interacting with an environment. Many clinicians in the field
of heart failure have observed that patients with different
phenotypes of cardiogenic shock may respond differently to
the pharmacologic and mechanical support strategies that are
available. Individual patient groups could be classified by
phenotypic presentations and may have variable risk-benefit
profiles, particularly when applying different therapeutic
strategies. Further, completed clinical trials in the field have
identified a marked heterogeneity in the cardiogenic shock
population, which confounds the results. Thus, there is a high
likelihood that the failure of the clinical trials to show
demonstrable improvement in outcomes for certain
therapeutic modalities, particularly mechanical circulatory
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support modalities, may be due to a lack of understanding of
hemodynamic variations and phenotypes.
To complicate matters, the definition of cardiogenic
shock has also varied between trials and guidelines.1 Most
definitions have minimal hemodynamic data and qualifiers as
inclusion or exclusion criteria, which makes comparing results
across studies difficult, if not impossible. As a proof of
concept, Seymour and colleagues looked at a noncardiac
population and were able to ascertain sepsis phenotypes
through cluster and multidimensional cluster techniques.3
Each phenotype had different immune responses and
outcomes. More recently, the Cardiogenic Shock Working
Group used a cluster demonstration to identify hemodynamic
phenotypes.4 However, the question now is, how do we use
phenotype knowledge in practice?
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Conclusion
Invasive hemodynamic assessment is important for
cardiogenic shock management. To understand how to more
precisely leverage invasive hemodynamic information,
however, more data is needed. For any patient profile,
complexity should be balanced with practicality. Etiology,
cardiomyopathy characteristics, and hemodynamics are
factors that can contribute to developing an optimal and
informative phenotype. A better understanding of the utility of
patient phenotyping in cardiogenic shock should help to
advance the field and optimize patient outcomes.
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References
When treating patients in the cardiac intensive care unit,
pathophysiology should be used to guide therapy, especially
for patients receiving mechanical circulatory support services.
By understanding and leveraging the knowledge of
physiology, one can begin to see the different hemodynamic
effects of our pharmacologic agents. Invasive hemodynamic
information can identify what the appropriate pharmacologic
therapy should be. If the patient is in classic cardiogenic shock
with high systemic vascular resistance, an agent that increases
contractility but also vasodilates would be ideal. However, if
the patient has a low systemic vascular resistance or a mixed
shock picture, adding a vasodilator may not be appropriate.
Instead, an agent that increases systemic vascular resistance
with or without increasing contractility might be better.
Historically, the pulmonary artery (PA) catheter has not
been recommended for this patient population. In
heterogeneous critical care populations, using a PA catheter
did not demonstrably change outcomes.5 The ESCAPE trial
confirmed the meta-analysis in an acute heart failure
population and did not show a demonstrable benefit in the use
of PA catheters for routine therapy. Thus, the PA catheter was
“put to rest” in the mid-2000s, but there has been a resurgence
in recent times. Today, cardiogenic shock and the use of
temporary mechanical circulatory support strategies may
benefit from an understanding of the hemodynamic and
metabolic profiles of these patients; thus, the American
College of Cardiology/American Heart Association
Guidelines now support the use of PA catheters in patients
with cardiogenic shock.
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